Immune-Onc Therapeutics: Products & infrastructure
Immune-Onc Therapeutics has 5 clinical trials on record, 1 under way.
Data updated Nov 22, 2026 · Back to the company report
Products
Immune-Onc Therapeutics has 5 clinical trials on record, 1 under way.
5clinical trials
1trials under way
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
phase 1 · completed · 38 participants · Advanced Solid Tumor
Sep 2022
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
phase 1 · completed · 22 participants · Solid Tumor, Adult
Apr 2022
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients …
phase 1 · completed · 91 participants · Solid Tumor, Adult
Sep 2021
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Adva…
phase 2 · under way · 518 participants · as a collaborator · Advanced Liver Cancers
Nov 2020
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
phase 1 · completed · 67 participants · AML With Monocytic Differentiation; CMML
Sep 2020
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
